opening , page-33

re: opening .www.gsk.com Paulhart,
How is it possible for GSK actions to boost Relenza supply to satisfy substantial orders weaken BTA's case? The whole case is based on GSK's failure to support Relenza in the past and not what GSK is going to do now or in the future! If GSK had supported Relenza, Relenza's volume and production capacity would be many times what it is now. Current developments can only strengthen BTA's case increasing the possibility of a settlement out of court!